Management of patients with neuroendocrine liver metastasis (NELM) remains controversial. We sought to compare the net health benefit (NHB) of hepatic resection (HR) versus intraarterial therapy (IAT) among patients with NELM.
A decision analytic Markov model was created to estimate and compare the cost effectiveness associated with different management strategies (HR vs IAT) for a simulated cohort of patients with NELM. The primary (base case) analysis was calculated based on a 57-year-old male patient with metachronous, symptomatic NELM that involved <25% of the liver in the absence of extrahepatic disease. The endpoints were quality-adjusted life-months (QALMs), quality-adjusted life-year (QALY), incremental cost-effectiveness ratio (ICER), and NHB.
In the base case analysis, HR was strongly favored over IAT providing NHB of 20.0 QALMs and an ICER of $8,427 per QALY. In the Monte Carlo simulation, the greatest NHB for HR was among patients with functioning/symptomatic NELM, regardless of liver tumor burden. In the symptomatic group, IAT was favored only in a minority of old patients (>60 years) with extrahepatic disease and synchronous NELM. In contrast, in patients with nonfunctioning/asymptomatic NELM, hepatic tumor burden was the most important variable and HR was always cost ineffective in large tumors, independent of patient age and extrahepatic disease characteristics.
A Markov decision model demonstrated that HR was the preferred strategy among patients with symptomatic NELM, regardless of hepatic disease burden. In contrast, IAT should be preferred for patients with large volume nonfunctioning/asymptomatic NELM.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- The epidemiology of gastroenteropancreatic neuroendocrine tumors.Endocrinol Metab Clin North Am. 2011; 40: 1-18
- A 5-decade analysis of 13,715 carcinoid tumors.Cancer. 2003; 97: 934-959
- Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach.Surgery. 2011; 149: 209-220
- Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.Endocr Relat Cancer. 2008; 15: 1083-1097
- Prognostic variables in patients with gastrointestinal carcinoid tumours.Br J Surg. 1994; 81: 1007-1009
- Prognostic factors in gastrointestinal endocrine tumors.Endocr Pathol. 2007; 18: 145-149
- Hepatic neuroendocrine metastases: does intervention alter outcomes?.J Am Coll Surg. 2000; 190: 432-445
- Islet cell carcinomas of the pancreas: a twenty-year experience.Surgery. 1988; 104: 1011-1017
- Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?.J Am Coll Surg. 1998; 187 (Discussion -3): 88-92
- Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.J Am Coll Surg. 2003; 197: 29-37
- Long-term survival after resection for primary hepatic carcinoid tumor.Ann Surg Oncol. 2003; 10: 1171-1175
- Chemotherapy for gastro-enteropancreatic endocrine tumours.Neuroendocrinology. 2004; 80: 79-84
- Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor.J Clin Oncol. 1984; 2: 1255-1259
- Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience.Endocr Relat Cancer. 2009; 16: 977-990
- Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis.Ann Surg Oncol. 2010; 17: 3129-3136
- ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.Neuroendocrinology. 2012; 95: 157-176
- Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors.AJR Am J Roentgenol. 2007; 188: 1201-1207
- Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization.AJR Am J Roentgenol. 2008; 190: 67-73
- Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience.Cancer J. 2003; 9: 261-267
- Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors.Eur Radiol. 2003; 13: 136-140
- Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors.Cancer. 1998; 83: 2293-2301
- Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.Cancer. 2005; 104: 1590-1602
- Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis.Ann Surg Oncol. 2011; 18: 3657-3665
- The Markov process in medical prognosis.Med Decis Making. 1983; 3: 419-458
- Markov models in medical decision making: a practical guide.Med Decis Making. 1993; 13: 322-338
- Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma.J Hepatol. 2013; 59: 300-307
- Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria.Hepatology. 2015; 61: 227-237
- Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis.Med Decis Making. 1998; 18: S68-80
- Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.Expert Rev Pharmacoecon Outcomes Res. 2008; 8: 165-178
Social Security Administration. Actuarial life table [cited 2014 Dec]. Available from: www.ssa.gov/oact/STATS/table4c6.html. Accessed December 30, 2014.
- Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine.JAMA. 1996; 276: 1339-1341
- The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma.World J Surg. 2015; 39: 1474-1484
- Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.Hepatology. 2010; 51: 165-173
- Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies.J Am Coll Surg. 2013; 216: 123-134
- Local therapies for hepatic metastases.J Natl Compr Canc Netw. 2013; 11: 153-160
- Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years.Surgery. 2001; 129: 170-175
Published online: May 18, 2015
Accepted: March 4, 2015
G.S. and A.V. contributed equally to this manuscript.
© 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.